All In Biotech

Drug Trial Radar · NCT06775405

A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized Infants

A Randomized, Double-blind, Placebo-controlled, Phase III Confirmatory Study to Evaluate the Efficacy, Safety, Tolerability, and Antiviral Activity of Repeated Oral Administration of AK0529 in Hospitalized Infants With Respiratory Syncytial Virus Infection

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

180

Actual

Start

Feb 29, 2024

Primary completion

Apr 7, 2025

Study completion Apr 16, 2025

Sponsor

Sponsor type
Industry
First posted
Jan 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 1 month, up to 24 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Respiratory syncytial virus (RSV) is the most common respiratory infectious pathogen recognized worldwide that poses serious health risks to infants, and an important cause of hospitalization for severe respiratory infections in infants. Serious respiratory problems such as pneumonia caused by RSV are one of the leading causes of death from respiratory diseases in infants. AK0529 targets the Pre-F (fusion) protein on the surface of the viral envelope. Specifically, it prevents the virus from invading uninfected cells and inhibits the fusion between host cells by inhibiting the fusion of the F (fusion) proteins on the surface of the RSV envelope, thus providing the effects of anti-RSV infection. This is a randomized, double-blind, placebo-controlled, multicenter, phase III clinical study to evaluate the efficacy and safety of AK0529 in hospitalized infants aged 1 to 24 months with RSV infection. Considering the benefits of AK0529 in the population with RSV infection, hospitalized infants with moderate to severe RSV infection were selected as the target population for this study.

Conditions

  • Respiratory Synctial Virus Infections

Interventions

  • AK0529Drug

    Active Substance: AK0529, Pharmaceutical Form: Enteric pellets, Route of Administration: Oral

  • PlaceboDrug

    Active Substance: Placebo, Pharmaceutical Form: Enteric pellets, Route of Administration: Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in the Wang bronchiolitis clinical scoreTime frame: Day 3 (48 hours)

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Children's Hospital, Capital Medical University

    Beijing, China

  • First Hospital of Jilin University

    Changchun, China

  • Hunan Provincial People's Hospital

    Changsha, China

  • West China Second University Hospital, Sichuan University

    Chengdu, China

  • Children's Hospital, Zhejiang University School of Medicine

    Hangzhou, China

  • Sanya Central Hospital, Hainan Third People's Hospital

    Sanya, China

  • Shanghai Children's Hospital, Shanghai Jiao Tong University

    Shanghai, China

  • Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine

    Shanghai, China

  • Shengjing Hospital of China Medical University

    Shenyang, China

  • Tianjin Children's Hospital(Longyan)

    Tianjin, China

  • Tianjin Children's Hospital(Machang)

    Tianjin, China

  • Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University

    Wenzhou, China

  • Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, China

  • Wuxi Children's Hospital

    Wuxi, China

  • First Affiliated Hospital of Xiamen University

    Xiamen, China

  • Women and Children's Hospital, and the School of Medicine, Xiamen University

    Xiamen, China

  • Zhongshan Women and Children's Hospital-Zhongshan Boai Hospital

    Zhongshan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.